Interleukin-5 Antagonist Monoclonal Antibody Therapy Improves Symptoms and Reduces Steroid Dependence in Eosinophilic Myocarditis Patients
oleh: Vincenzo Trovato, MD, Ashlee Asada, MD, Lynn Fussner, MD, Casey Curtis, MD, Rami Kahwash, MD
| Format: | Article |
|---|---|
| Diterbitkan: | Elsevier 2024-04-01 |
Deskripsi
Eosinophilic myocarditis (EM) is a rare disease associated with significant morbidity and mortality. This case series follows the clinical courses of 3 patients with EM. The use of mepolizumab, an anti–interleukin-5 monoclonal antibody, as an adjunctive treatment was associated with stabilization of cardiac function and improved long-term outcomes.